source
- Pathos AI signs major ADC partnership with Chinese biotech Alphamab and targets up to $300M Series E raisePathos AI, a technology and drug development company, announced a major antibody‑drug conjugate (ADC) collaboration with Chinese biotech Alphamab. The firm also disclosed a partnership with AstraZ…
- Patient finds open-source diabetes app improves control despite lack of FDA approvalPatient has type 1 diabetes for over 30 years and has used FDA-approved pumps and sensors that were upgraded roughly every five years. Over time his glucose control slipped despite the regulated de…